Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBT: 2010-2025

Historic EBT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $51.5 million.

  • Arrowhead Pharmaceuticals' EBT rose 120.90% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year increase of 108.41%. This contributed to the annual value of $51.5 million for FY2025, which is 108.41% up from last year.
  • Arrowhead Pharmaceuticals' EBT amounted to $51.5 million in FY2025, which was up 108.41% from -$612.5 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year EBT high stood at $51.5 million for FY2025, and its period low was -$612.5 million during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EBT value was -$206.5 million (recorded in 2023), while the average stood at -$255.8 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' EBT crashed by 196.60% in 2024 and then surged by 108.41% in 2025.
  • Arrowhead Pharmaceuticals' EBT (Yearly) stood at -$140.8 million in 2021, then declined by 22.62% to -$172.7 million in 2022, then decreased by 19.56% to -$206.5 million in 2023, then tumbled by 196.60% to -$612.5 million in 2024, then soared by 108.41% to $51.5 million in 2025.